Tirzepatide 10mg

Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight near 4810.5 Da. Its backbone is built on the GIP sequence rather than the GLP-1 sequence, with substitutions that add GLP-1 receptor activity. The compound is often called a GLP-1 analogue, when its backbone is closer to GIP.

A C20 fatty diacid is attached to the peptide. The chain binds serum albumin, which slows clearance and gives the molecule a half-life around five days. Albumin binding, not the peptide sequence, is what makes once-weekly dosing possible in the clinical literature.

The receptor profile is uneven. Published work characterises tirzepatide as an imbalanced and biased dual agonist: closer to native GIP at GIPR, and weaker at GLP-1R than GLP-1 itself, with signalling bias between cAMP accumulation and beta-arrestin recruitment. Researchers studying receptor bias use it precisely because the imbalance is measurable.

The SURPASS programme measured glycaemic and body-weight endpoints in type 2 diabetes. Those are published trial findings, not outcomes we attribute to this product.

Retatrutide adds a third receptor to this same incretin background, which is the usual reason to run the two side by side.

Supplied as a lyophilised powder at ≥99% purity by HPLC, with batch LC-MS identity confirmation and a certificate of analysis. Reconstitute with bacteriostatic water. Store the sealed vial at -20°C and keep reconstituted solution at 2-8°C, protected from light.

For in-vitro laboratory research only. Not for human or veterinary use.